Affirm Partners with VersaClimber to Bring Consumers a Better Way to Pay
VersaClimber available in simple monthly payments, with no hidden or late fees SAN FRANCISCO–(BUSINESS WIRE)–Affirm…
Social Media
Lucy Scientific Discovery Announces Partnership with High Times® to Develop and Distribute a New Line of Psychoactive Products
‘Mindful by Lucy’ Mushroom Microdose Supplements VANCOUVER, British Columbia, March 23, 2023 (GLOBE NEWSWIRE) —…
Lucy Scientific Discovery Announces Partnership with High Times® to Develop and Distribute a New Line of Psychoactive Products
‘Mindful by Lucy’ Mushroom Microdose Supplements VANCOUVER, British Columbia, March 23, 2023 (GLOBE NEWSWIRE) —…
Eledon to Present Data from Ongoing Phase 1b Trial Evaluating Tegoprubart in Kidney Transplantation at the World Congress of Nephrology 2023
Additional poster presentation to detail high-dose cohort safety data from Phase 2a trial of tegoprubart…
Eledon to Present Data from Ongoing Phase 1b Trial Evaluating Tegoprubart in Kidney Transplantation at the World Congress of Nephrology 2023
Additional poster presentation to detail high-dose cohort safety data from Phase 2a trial of tegoprubart…
Genelux Corporation to Ring Nasdaq Opening Bell on March 29, 2023
WESTLAKE VILLAGE, Calif., March 23, 2023 (GLOBE NEWSWIRE) — Genelux Corporation (NASDAQ: GNLX) (“Genelux” or…
Genelux Corporation to Ring Nasdaq Opening Bell on March 29, 2023
WESTLAKE VILLAGE, Calif., March 23, 2023 (GLOBE NEWSWIRE) — Genelux Corporation (NASDAQ: GNLX) (“Genelux” or…
Monopar Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Developments
Validive® Phase 2b/3 VOICE Trial Anticipates Go/No-Go Interim Readout by End of Next WeekCamsirubicin Phase…
Monopar Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Developments
Validive® Phase 2b/3 VOICE Trial Anticipates Go/No-Go Interim Readout by End of Next WeekCamsirubicin Phase…
Press Release: Dupixent® demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial
Dupixent® demonstrates potential to become first biologic to treat COPD by showing significant reduction in…
Dupixent® (dupilumab) Demonstrates Potential to Become First Biologic to Treat COPD by Showing Significant Reduction in Exacerbations in Pivotal Trial
First and only biologic to demonstrate clinically meaningful and statistically significant reduction (30%) in exacerbations…
Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS
SOD1-ALS is a rare genetic form of the disease affecting approximately 330 people in the…
Senti Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Reviews Recent Highlights
– SENTI-202 on track to submit an Investigational New Drug (IND) application in second half…
PMI study reveals project management gender divide across all major industries
Collaboration between Project Management Institute and Women of Project Management to boost inclusion in the…
Fanatics to Become the National Hockey League’s Official On-Ice Uniform Outfitter Starting with the 2024-25 Season
Fanatics currently makes and supplies Authentic Pro performance and training products for the NHL, and…
Press Release: Dupixent® (dupilumab) approved by European Commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis
Dupixent® (dupilumab) approved by European Commission as first and only targeted medicine for children as…
Dupixent® (dupilumab) Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis
Approximately seven times as many patients aged 6 months to 5 years with severe atopic…
Medallia Named the Leader in Customer Feedback Management Platforms
Independent Research Firm report says Medallia “breaks away from competition with depth and breadth of…
Press Release: Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis
Dupixent®(dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic…
Dupixent® (dupilumab) Late-Breaking Data at AAD Show Significant Improvements in Signs and Symptoms of Moderate-to-severe Atopic Hand and Foot Dermatitis
More than twice as many patients on Dupixent achieved clear or almost clear skin compared…